RFC40 Modulation for Triple-Negative Breast Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current breast cancer treatments lack effective therapies for triple-negative breast cancer (TNBC) due to its lack of estrogen, progesterone, and HER2 receptors, necessitating the identification of non-receptor based molecular targets for diagnosis and therapy.
Innovation Solution
RFC40 is identified and validated as a non-receptor based molecular marker and target for breast cancer, with methods involving the modulation of its expression or activity using inhibitors like siRNAs, miRNAs, and antibodies to inhibit cell proliferation and division, applicable to all breast cancer subtypes including TNBC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional endocrine and growth factor receptor-based therapies are used for breast cancer treatment, then treatment effectiveness is improved for estrogen-positive and HER2-overexpressing cancers, but treatment is ineffective for triple-negative breast cancer (TNBC) which lacks these receptors
Solution Approach 1:
The patent identifies RFC40 as a universal therapeutic target that functions across all breast cancer subtypes (estrogen-positive, HER2-overexpressing, and triple-negative cancers). RFC40 inhibition provides a multi-functional approach that replaces the need for subtype-specific receptor-targeted therapies, making a single treatment strategy effective for diverse cancer types.
Solution Approach 2:
The patent extracts the therapeutic target from receptor-based pathways and identifies RFC40, a non-receptor protein involved in DNA replication, as an alternative target. This extraction allows treatment to bypass the limitation of receptor absence in TNBC by targeting a different molecular pathway essential for cancer cell proliferation.
2Measurement precision
If breast cancer therapies focus on receptor-based targets, then treatment specificity is improved for receptor-positive cancers, but therapeutic options are limited for cancers lacking these receptors
Solution Approach 1:
The patent introduces RFC40 as an intermediary target that mediates cancer cell proliferation through DNA replication processes. By targeting this intermediary mechanism rather than the original receptor pathways, the invention provides a new therapeutic entry point that is accessible to all breast cancer subtypes regardless of receptor status.
Solution Approach 2:
The patent changes the therapeutic parameter from targeting surface receptors (external cell membrane proteins) to targeting RFC40 (an intracellular DNA replication protein). This parameter change shifts the treatment approach from extracellular signaling blockade to intracellular replication inhibition, expanding therapeutic options for receptor-negative cancers.
3Adaptability or versatility
If non-receptor based targets are identified for TNBC treatment, then therapeutic versatility is improved across all breast cancer subtypes, but the complexity of identifying and validating new molecular targets increases
Solution Approach 1:
The patent segments the complex task of finding universal cancer targets by focusing on essential cellular processes (DNA replication) that are common to all rapidly dividing cells. By breaking down the search for therapeutic targets into functional categories, the invention systematically identified RFC40 as a critical component of DNA replication that serves as a viable universal target.
Data Source
AI summary
The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.